Takayasu ||| S:0 E:8 ||| NNP
's  ||| S:8 E:11 ||| POS
arteritis  ||| S:11 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
Turkey  ||| S:24 E:31 ||| NNP
-  ||| S:31 E:33 ||| :
clinical  ||| S:33 E:42 ||| JJ
and  ||| S:42 E:46 ||| CC
angiographic  ||| S:46 E:59 ||| JJ
features  ||| S:59 E:68 ||| NNS
of  ||| S:68 E:71 ||| IN
248  ||| S:71 E:75 ||| CD
patients  ||| S:75 E:84 ||| NNS
Takayasu ||| S:84 E:92 ||| NNP
's  ||| S:92 E:95 ||| POS
arteritis  ||| S:95 E:105 ||| NN
( ||| S:105 E:106 ||| -LRB-
TA ||| S:106 E:108 ||| NNP
)  ||| S:108 E:110 ||| -RRB-
is  ||| S:110 E:113 ||| VBZ
a  ||| S:113 E:115 ||| DT
chronic ||| S:115 E:122 ||| NN
,  ||| S:122 E:124 ||| ,
inflammatory  ||| S:124 E:137 ||| JJ
vasculitis  ||| S:137 E:148 ||| NNS
affecting  ||| S:148 E:158 ||| VBG
the  ||| S:158 E:162 ||| DT
aorta  ||| S:162 E:168 ||| NN
and  ||| S:168 E:172 ||| CC
its  ||| S:172 E:176 ||| PRP$
major  ||| S:176 E:182 ||| JJ
branches ||| S:182 E:190 ||| NNS
.  ||| S:190 E:192 ||| .
Although  ||| S:192 E:201 ||| IN
it  ||| S:201 E:204 ||| PRP
is  ||| S:204 E:207 ||| VBZ
more  ||| S:207 E:212 ||| RBR
prevalent  ||| S:212 E:222 ||| JJ
in  ||| S:222 E:225 ||| IN
Far-East  ||| S:225 E:234 ||| NNP
Asia ||| S:234 E:238 ||| NNP
,  ||| S:238 E:240 ||| ,
the  ||| S:240 E:244 ||| DT
distribution  ||| S:244 E:257 ||| NN
of  ||| S:257 E:260 ||| IN
the  ||| S:260 E:264 ||| DT
disease  ||| S:264 E:272 ||| NN
is  ||| S:272 E:275 ||| VBZ
worldwide  ||| S:275 E:285 ||| VBN
with  ||| S:285 E:290 ||| IN
different  ||| S:290 E:300 ||| JJ
vascular  ||| S:300 E:309 ||| JJ
involvement  ||| S:309 E:321 ||| NN
patterns  ||| S:321 E:330 ||| NNS
and  ||| S:330 E:334 ||| CC
clinical  ||| S:334 E:343 ||| JJ
manifestations ||| S:343 E:357 ||| NNS
.  ||| S:357 E:359 ||| .
The  ||| S:359 E:363 ||| DT
objective  ||| S:363 E:373 ||| NN
of  ||| S:373 E:376 ||| IN
this  ||| S:376 E:381 ||| DT
study  ||| S:381 E:387 ||| NN
was  ||| S:387 E:391 ||| VBD
to  ||| S:391 E:394 ||| TO
evaluate  ||| S:394 E:403 ||| VB
the  ||| S:403 E:407 ||| DT
demographic ||| S:407 E:418 ||| JJ
,  ||| S:418 E:420 ||| ,
clinical ||| S:420 E:428 ||| JJ
,  ||| S:428 E:430 ||| ,
angiographic  ||| S:430 E:443 ||| NN
and  ||| S:443 E:447 ||| CC
prognostic  ||| S:447 E:458 ||| JJ
features  ||| S:458 E:467 ||| NNS
of  ||| S:467 E:470 ||| IN
TA  ||| S:470 E:473 ||| NNP
patients  ||| S:473 E:482 ||| NNS
in  ||| S:482 E:485 ||| IN
Turkey ||| S:485 E:491 ||| NNP
.  ||| S:491 E:493 ||| .
Clinical  ||| S:493 E:502 ||| JJ
and  ||| S:502 E:506 ||| CC
angiographic  ||| S:506 E:519 ||| JJ
findings  ||| S:519 E:528 ||| NNS
of  ||| S:528 E:531 ||| IN
248  ||| S:531 E:535 ||| CD
TA  ||| S:535 E:538 ||| NNP
patients  ||| S:538 E:547 ||| NNS
( ||| S:547 E:548 ||| -LRB-
228  ||| S:548 E:552 ||| CD
female ||| S:552 E:558 ||| NN
,  ||| S:558 E:560 ||| ,
27  ||| S:560 E:563 ||| CD
male ||| S:563 E:567 ||| NN
)  ||| S:567 E:569 ||| -RRB-
followed  ||| S:569 E:578 ||| VBD
at  ||| S:578 E:581 ||| IN
15  ||| S:581 E:584 ||| CD
Rheumatology  ||| S:584 E:597 ||| NNP
Centers  ||| S:597 E:605 ||| NNPS
were  ||| S:605 E:610 ||| VBD
prospectively  ||| S:610 E:624 ||| RB
evaluated  ||| S:624 E:634 ||| VBN
according  ||| S:634 E:644 ||| VBG
to  ||| S:644 E:647 ||| TO
a  ||| S:647 E:649 ||| DT
predefined  ||| S:649 E:660 ||| JJ
protocol ||| S:660 E:668 ||| NN
.  ||| S:668 E:670 ||| .
The  ||| S:670 E:674 ||| DT
mean  ||| S:674 E:679 ||| JJ
age  ||| S:679 E:683 ||| NN
was  ||| S:683 E:687 ||| VBD
40.1  ||| S:687 E:692 ||| CD
years  ||| S:692 E:698 ||| NNS
( ||| S:698 E:699 ||| -LRB-
30.2  ||| S:699 E:704 ||| CD
years  ||| S:704 E:710 ||| NNS
at  ||| S:710 E:713 ||| IN
the  ||| S:713 E:717 ||| DT
clinical  ||| S:717 E:726 ||| JJ
onset ||| S:726 E:731 ||| NN
) ||| S:731 E:732 ||| -RRB-
.  ||| S:732 E:734 ||| .
Clinical  ||| S:734 E:743 ||| JJ
manifestations  ||| S:743 E:758 ||| NNS
included  ||| S:758 E:767 ||| VBD
constitutional  ||| S:767 E:782 ||| JJ
symptoms  ||| S:782 E:791 ||| NNS
in  ||| S:791 E:794 ||| IN
66 ||| S:794 E:796 ||| CD
% ||| S:796 E:797 ||| NN
,  ||| S:797 E:799 ||| ,
absent  ||| S:799 E:806 ||| JJ
or  ||| S:806 E:809 ||| CC
diminished  ||| S:809 E:820 ||| JJ
pulses  ||| S:820 E:827 ||| NN
in  ||| S:827 E:830 ||| IN
88 ||| S:830 E:832 ||| CD
% ||| S:832 E:833 ||| NN
,  ||| S:833 E:835 ||| ,
bruits  ||| S:835 E:842 ||| VBG
in  ||| S:842 E:845 ||| IN
77 ||| S:845 E:847 ||| CD
% ||| S:847 E:848 ||| NN
,  ||| S:848 E:850 ||| ,
extremity  ||| S:850 E:860 ||| JJ
pain  ||| S:860 E:865 ||| NN
in  ||| S:865 E:868 ||| IN
69 ||| S:868 E:870 ||| CD
% ||| S:870 E:871 ||| NN
,  ||| S:871 E:873 ||| ,
claudication  ||| S:873 E:886 ||| NN
in  ||| S:886 E:889 ||| IN
48 ||| S:889 E:891 ||| CD
% ||| S:891 E:892 ||| NN
,  ||| S:892 E:894 ||| ,
hypertension  ||| S:894 E:907 ||| NN
in  ||| S:907 E:910 ||| IN
43 ||| S:910 E:912 ||| CD
%  ||| S:912 E:914 ||| NN
and  ||| S:914 E:918 ||| CC
cerebrovascular  ||| S:918 E:934 ||| JJ
accidents  ||| S:934 E:944 ||| NNS
( ||| S:944 E:945 ||| -LRB-
CVA ||| S:945 E:948 ||| NNP
)  ||| S:948 E:950 ||| -RRB-
in  ||| S:950 E:953 ||| IN
18 ||| S:953 E:955 ||| CD
%  ||| S:955 E:957 ||| NN
of  ||| S:957 E:960 ||| IN
the  ||| S:960 E:964 ||| DT
patients ||| S:964 E:972 ||| NNS
.  ||| S:972 E:974 ||| .
Renal  ||| S:974 E:980 ||| JJ
artery  ||| S:980 E:987 ||| NN
stenosis ||| S:987 E:995 ||| NN
,  ||| S:995 E:997 ||| ,
aortic  ||| S:997 E:1004 ||| JJ
regurgitation  ||| S:1004 E:1018 ||| NN
and  ||| S:1018 E:1022 ||| CC
pulmonary  ||| S:1022 E:1032 ||| JJ
hypertension  ||| S:1032 E:1045 ||| NN
were  ||| S:1045 E:1050 ||| VBD
present  ||| S:1050 E:1058 ||| JJ
in  ||| S:1058 E:1061 ||| IN
26 ||| S:1061 E:1063 ||| CD
% ||| S:1063 E:1064 ||| NN
,  ||| S:1064 E:1066 ||| ,
33 ||| S:1066 E:1068 ||| CD
%  ||| S:1068 E:1070 ||| NN
and  ||| S:1070 E:1074 ||| CC
12 ||| S:1074 E:1076 ||| CD
% ||| S:1076 E:1077 ||| NN
,  ||| S:1077 E:1079 ||| ,
respectively ||| S:1079 E:1091 ||| RB
.  ||| S:1091 E:1093 ||| .
According  ||| S:1093 E:1103 ||| VBG
to  ||| S:1103 E:1106 ||| TO
the  ||| S:1106 E:1110 ||| DT
new  ||| S:1110 E:1114 ||| JJ
angiographic  ||| S:1114 E:1127 ||| JJ
classification ||| S:1127 E:1141 ||| NN
,  ||| S:1141 E:1143 ||| ,
type  ||| S:1143 E:1148 ||| NN
V  ||| S:1148 E:1150 ||| NNP
( ||| S:1150 E:1151 ||| -LRB-
50.8 ||| S:1151 E:1155 ||| CD
% ||| S:1155 E:1156 ||| NN
)  ||| S:1156 E:1158 ||| -RRB-
and  ||| S:1158 E:1162 ||| CC
Type  ||| S:1162 E:1167 ||| NNP
I  ||| S:1167 E:1169 ||| NNP
( ||| S:1169 E:1170 ||| -LRB-
32 ||| S:1170 E:1172 ||| CD
% ||| S:1172 E:1173 ||| NN
)  ||| S:1173 E:1175 ||| -RRB-
were  ||| S:1175 E:1180 ||| VBD
the  ||| S:1180 E:1184 ||| DT
most  ||| S:1184 E:1189 ||| RBS
frequent  ||| S:1189 E:1198 ||| JJ
types  ||| S:1198 E:1204 ||| NNS
of  ||| S:1204 E:1207 ||| IN
involvement ||| S:1207 E:1218 ||| NN
.  ||| S:1218 E:1220 ||| .
Corticosteroids  ||| S:1220 E:1236 ||| NNP
were  ||| S:1236 E:1241 ||| VBD
the  ||| S:1241 E:1245 ||| DT
main  ||| S:1245 E:1250 ||| JJ
treatment  ||| S:1250 E:1260 ||| NN
in  ||| S:1260 E:1263 ||| IN
93 ||| S:1263 E:1265 ||| CD
%  ||| S:1265 E:1267 ||| NN
of  ||| S:1267 E:1270 ||| IN
the  ||| S:1270 E:1274 ||| DT
patients  ||| S:1274 E:1283 ||| NNS
alone  ||| S:1283 E:1289 ||| RB
( ||| S:1289 E:1290 ||| -LRB-
9 ||| S:1290 E:1291 ||| CD
% ||| S:1291 E:1292 ||| NN
)  ||| S:1292 E:1294 ||| -RRB-
or  ||| S:1294 E:1297 ||| CC
in  ||| S:1297 E:1300 ||| IN
combination  ||| S:1300 E:1312 ||| NN
with  ||| S:1312 E:1317 ||| IN
immunosuppressive  ||| S:1317 E:1335 ||| JJ
agents  ||| S:1335 E:1342 ||| NNS
( ||| S:1342 E:1343 ||| -LRB-
84 ||| S:1343 E:1345 ||| CD
% ||| S:1345 E:1346 ||| NN
) ||| S:1346 E:1347 ||| -RRB-
.  ||| S:1347 E:1349 ||| .
Most  ||| S:1349 E:1354 ||| RBS
frequently  ||| S:1354 E:1365 ||| RB
preferred  ||| S:1365 E:1375 ||| VBN
immunosuppressive  ||| S:1375 E:1393 ||| JJ
agents  ||| S:1393 E:1400 ||| NNS
were  ||| S:1400 E:1405 ||| VBD
methotrexate  ||| S:1405 E:1418 ||| NNS
( ||| S:1418 E:1419 ||| -LRB-
63 ||| S:1419 E:1421 ||| CD
% ||| S:1421 E:1422 ||| NN
) ||| S:1422 E:1423 ||| -RRB-
,  ||| S:1423 E:1425 ||| ,
azathioprine  ||| S:1425 E:1438 ||| NNS
( ||| S:1438 E:1439 ||| -LRB-
22 ||| S:1439 E:1441 ||| CD
% ||| S:1441 E:1442 ||| NN
)  ||| S:1442 E:1444 ||| -RRB-
and  ||| S:1444 E:1448 ||| CC
cyclophosphamide  ||| S:1448 E:1465 ||| NNS
( ||| S:1465 E:1466 ||| -LRB-
13 ||| S:1466 E:1468 ||| CD
% ||| S:1468 E:1469 ||| NN
) ||| S:1469 E:1470 ||| -RRB-
.  ||| S:1470 E:1472 ||| .
Remission  ||| S:1472 E:1482 ||| NNP
was  ||| S:1482 E:1486 ||| VBD
observed  ||| S:1486 E:1495 ||| VBN
at  ||| S:1495 E:1498 ||| IN
least  ||| S:1498 E:1504 ||| JJS
once  ||| S:1504 E:1509 ||| RB
in  ||| S:1509 E:1512 ||| IN
94 ||| S:1512 E:1514 ||| CD
%  ||| S:1514 E:1516 ||| NN
of  ||| S:1516 E:1519 ||| IN
the  ||| S:1519 E:1523 ||| DT
patients  ||| S:1523 E:1532 ||| NNS
and  ||| S:1532 E:1536 ||| CC
sustained  ||| S:1536 E:1546 ||| VBD
remission  ||| S:1546 E:1556 ||| VBN
in  ||| S:1556 E:1559 ||| IN
71 ||| S:1559 E:1561 ||| CD
%  ||| S:1561 E:1563 ||| NN
during  ||| S:1563 E:1570 ||| IN
follow-up ||| S:1570 E:1579 ||| JJ
.  ||| S:1579 E:1581 ||| .
The  ||| S:1581 E:1585 ||| DT
demographical ||| S:1585 E:1598 ||| NN
,  ||| S:1598 E:1600 ||| ,
clinical  ||| S:1600 E:1609 ||| JJ
and  ||| S:1609 E:1613 ||| CC
angiographic  ||| S:1613 E:1626 ||| JJ
findings  ||| S:1626 E:1635 ||| NNS
of  ||| S:1635 E:1638 ||| IN
TA  ||| S:1638 E:1641 ||| NNP
patients  ||| S:1641 E:1650 ||| NNS
in  ||| S:1650 E:1653 ||| IN
our  ||| S:1653 E:1657 ||| PRP$
series  ||| S:1657 E:1664 ||| NN
were  ||| S:1664 E:1669 ||| VBD
similar  ||| S:1669 E:1677 ||| JJ
to  ||| S:1677 E:1680 ||| TO
those  ||| S:1680 E:1686 ||| DT
reported  ||| S:1686 E:1695 ||| VBN
from  ||| S:1695 E:1700 ||| IN
Japan ||| S:1700 E:1705 ||| NNP
,  ||| S:1705 E:1707 ||| ,
Brazil  ||| S:1707 E:1714 ||| NNP
and  ||| S:1714 E:1718 ||| CC
Colombia ||| S:1718 E:1726 ||| NNP
.  ||| S:1726 E:1728 ||| .
Combination  ||| S:1728 E:1740 ||| NN
therapies  ||| S:1740 E:1750 ||| NNS
with  ||| S:1750 E:1755 ||| IN
immunosuppressive  ||| S:1755 E:1773 ||| JJ
agents  ||| S:1773 E:1780 ||| NNS
were  ||| S:1780 E:1785 ||| VBD
the  ||| S:1785 E:1789 ||| DT
preferred  ||| S:1789 E:1799 ||| JJ
choice  ||| S:1799 E:1806 ||| NN
of  ||| S:1806 E:1809 ||| IN
treatment  ||| S:1809 E:1819 ||| NN
in  ||| S:1819 E:1822 ||| IN
Turkey ||| S:1822 E:1828 ||| NNP
.  ||| S:1828 E:1830 ||| .
